Helmut
★★★
avatar
Homepage
Vienna, Austria,
2013-01-22 00:06
(4890 d 01:54 ago)

Posting: # 9895
Views: 6,439
 

 Brave New World (no pun!) [Two-Stage / GS Designs]

Sequential Designs and Interim Analyses
in Bioequivalence: FDA’s
Experience


Barbara M. Davit, Ph.D., J.D.
Director, Division of Bioequivalence II
Office of Generic Drugs, CDER, FDA

Mini-Symposium on Adaptive Study Designs and Assessment
Approaches for Bioequivalence
AAPS Annual Meeting
Chicago, IL
October 13-18, 2012


[image]

[image]



P.S.: No slide about Method B. :-D

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
ElMaestro
★★★

Denmark,
2013-01-22 11:51
(4889 d 14:09 ago)

@ Helmut
Posting: # 9896
Views: 5,189
 

 Brave New World (no pun!)

Hi Helmut,

thanks for posting. I think this is a step in the right direction. To me meffud B and C are pretty similar in terms of the work needed to plan and conduct the study, and since the two meffuds have nearly equal performance I have little or no preference myself. I am just happy FDA is giving one of them the green light.

Now we just need some considerations over stoping criteria and higher target power than 80% :-D and oooohh aaah parallel studies.

Have a great day.

Pass or fail!
ElMaestro
UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
145 visitors (0 registered, 145 guests [including 48 identified bots]).
Forum time: 03:00 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5